|
CN111542538A
|
|
CD 9P-1-targeting antibodies and uses thereof
|
|
WO2019020807A1
|
|
Cd9p-1-targeting antibody and uses thereof
|
|
AU2018214221A1
|
|
Sterile formulation comprising a stable phosphorothioate oligonucleotide
|
|
EP3576753A1
|
|
Sterile formulation comprising a stable phosphorothioate oligonucleotide
|
|
US2018221401A1
|
|
Sterile formulation comprising a stable phosphorothioate oligonucleotide
|
|
WO2017025471A1
|
|
Sterile emulsion comprising a stable phosphorothioate oligonucleotide
|
|
US2017035693A1
|
|
Sterile Emulsion Comprising a Stable Phosphorothioate Oligonucleotide
|
|
EP3128007A1
|
|
Sterile emulsion comprising a stable phosphorothioate oligonucleotide
|
|
EP2907823A1
|
|
Polypeptide fragments of 168A-T2 and compositions comprising them for use in treating cancer
|
|
US2015283165A1
|
|
Use of an inhibitor of irs-1 for treating skin disorders
|
|
EP2682467A1
|
|
Use of an inhibitor of IRS-1 for treating skin disorders
|
|
AU2012277722A1
|
|
Composition comprising inhibitors of IRS-1 and of VEGF
|
|
WO2012085096A1
|
|
Peptides for treating cancer
|
|
EP2540828A1
|
|
Composition comprising inhibitors of IRS-1 and of VEGF
|
|
US2013004511A1
|
|
Composition comprising inhibitors of irs-1 and of vegf
|
|
CA2802471A1
|
|
Novel peptides for wound healing
|
|
EP2468288A1
|
|
Peptides for treating cancer
|
|
EP2418279A1
|
|
Injectable pharmaceutical composition for preventing, stabilising and/or inhibiting pathological neovascularization-related conditions
|
|
EP2395015A1
|
|
Peptides for wound healing
|
|
EP2158317A1
|
|
Anti-tumor drug, medicament, composition, and use thereof
|
